DAFTAR PUSTAKA

Almutrafi, Amna., Bashawry, Yara., AlShakweer, Wafaa., Al-Harbi, Musa., Altwairgi, Abdullah and Al-Dandan, Sadeq., (2020). *Research Article The Epidemiology of Primary Central Nervous System Tumors at the National Neurologic Institute in Saudi Arabia: A Ten-Year Single-Institution Study.* Journal of Cancer Epidemiology Volume 2020 : 1-9. https://doi.org/10.1155/2020/1429615.

Apra, Caroline., Peyre, Matthieu., and Kalamarides. Michel. (2018). *Current treatment options for meningioma.* Expert Review of Neurotherapeutics, Expert Reviews (formerly Future Drugs),18 (3) : 241- 249. https://doi.org/10.1080/14737175.2018.1429920.

Asghar, U., Agnieszka K., Witkiewicz A., Turner N., & Erik S. Knudsen. (2015). *The history and future of targeting cyclin-dependent kinases in cancer therapys.* Nat Rev Drug Discov; 14(2): 130-146. doi:10.1038/nrd4504

Benson, VS., Pirie, K., Green, J., Casabonne, D., and Beral, V. (2008). *Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort.* Br J Cancer. 99(1):185-90doi:10.1038/sj.bjc.6604445.

Brown, Nicholas R., Korolchuk, Svitlana., Martin, Mathew P., Stanley, Will A., Moukhametzianov, Rouslan., Noble , Martin E.M. & Endicott,

Jane A. (2015). *CDK1 structures reveal conserved and unique features of the essential cell cycle CDK*. NATURE COMMUNICATIONS (6) : 6769. P : 1-11. DOI: 10.1038/ncomms7769

Ching Wu, Jau. (2014). *Risk factors of meningioma.* Journal of Chinese Medical Association 77 : 451-452. http://dx.doi.org/10.1016/j.jcma.2014.07.005.

Choy, Winward., Kim, Won., Nagasawa, D., Stramotas, S., Yew, A., Gopen, Q., Parsa, AT., and Yang, Isaac. (2011). *The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments*. Neurosurg Focus. Vol 30 (E6) : 1-12. DOI: 10.3171/2011.2.FOCUS1116.

Commins, Deborah L., Atkinson, Roscoe D., and Burnett, Margaret E. (2007). *Review of meningioma histopathology.* Neurosurg Focus 23 (4): 1-9. DOI: 10.3171/FOC-07/10/E3.

Cossu, Giulia et all. (2016). *Meningiomas 'Management : An Update of he Literature'.* Researchgate Neurooncology Chapter 15 : 361-372. Doi : 10.5772/62929.

Dickson, M.A., and Schwartz, G.K. (2009). *Development of cell-cycle inhibitors for cancer therapy*. Current Oncology Volume 16 (2) : 36-40.

Domingues, P. *et al.* (2015). *'Genetic/Molecular Alterations of Meningiomas and the Signaling Pathways Targeted', Oncotarget*, 6(13), pp. 10671–10688. doi: 10.18632/oncotarget.3870

Goldbrunner, Roland et all. (2016). *EANO Guidelines for the Diagnosis and Treatment of Meningiomas.* Lancet Oncol volume 17 : e383-e391.

Ikeri, N. Z., Anunobi, C. C. and Bankole, O. B. (2018). *Progesterone Receptor Expression and Ki - 67   Labelling Index of Meningiomas in the Lagos University Teaching Hospital'*, Nigerian Postgraduate Medical Journal, 25, pp. 17–20. doi: 10.4103/npmj.npmj.

Juric, Viktorija. & Brona Murphy. (2019). *Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions. Journal of Cancer Drug Resist* 3:48-62 http://dx.doi.org/10.20517/cdr.2019.105

Kalous, Jaroslav., Denisa, Jansova,.& Andrej Susor. (2020). *Role of Cycli-Dependent Kinase 1 in Translational Regulation in a M-Phase. Journal   MDPI   vol.9(1568)   :   5-14* https://doi.org/10.3390/cells9071568.

Kemenkes RI. (2019). *Pedoman Nasional Pelayanan Kedokteran Tumor Otak.* Jakarta : Komite Penanggulangan Kanker Nasional.

Kim, Min Soo., et all. (2014). *Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas.*

J Neurosurg 121:1189–1200. http://thejns.org/doi/abs/10.3171/2014.7.JNS132661.

Kumar, V., Abbas, A. K. and J. C. Aster, (eds) (2015) 'The Cell as a Unit of Health and Disease', in Robbins and Cotran Pathologic Basis of Disease. 9th edition. Philadelphia : Saunders, an imprint of Elsevier Inc., pp. 25-26.

Louis, David N et all. (2021). *The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.* Neuro-Oncology 23(8), 1231–1251. doi:10.1093/neuonc/noab106.

Ogasawara, Christian., Philbrick, Brandon D., and Adamson, Cory D. (2021). *Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions.* Biomedicines 9, 319 : 1-23. https://doi.org/10.3390/biomedicines9030319.

Ostrom, Quinn T., Patil, Nirav., Cioffi, Gino., Waite, Kristin., Kruchko, Carol., and Sloan Jill S. Barnholtz. (2020). *CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017.* Neuro-Oncology 22(S1), 1–96, 2020. doi:10.1093/neuonc/noaa200

Patel, JP., Jansari, TR., and Chaudhari, VV. (2019). *Clinicopathological study of Meningioma.* Tropical Journal of Pathology and

Microbiology Volume 6 Number 1 : 9-17. DOI:

https://doi.org/10.17511/jopm.2020.i01.02.

Perry, A., Louis, D.N., Budka, H., von Deimling, A., Sahm, F., Rushing, E.j. (2016). *"Meningioma" in WHO Classification of Tumours of The Central Nervous System 4th edition.* Lyon : International Agency for Research on Cancer (IARC). pp. 232-245

Peyressatre, Marion., Prevel, Camille., Pellerano, Morgan and May C. Morris. (2015). *Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors.* Cancers 2015, 7 : 179-237. doi:10.3390/cancers7010179

Santamarıa, David., et all. (2007). *Cdk1 is sufficient to drive the mammalian cell cycle.* Nature Vol 448 : 811-815. doi: https://doi.org/10.1038/nature06046.

Schniederjan, Matthew J. (2018). *Biopsy Intrepretation of The Central Nervous System 2nd Edition.* Philadelpia : Wolter Klower.

Sung, Wen Wei., . (2014). *High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.* BMC Cancer 2014, 14:951 http://www.biomedcentral.com/1471-2407/14/951

Venura, Vyshak Alva., Santagatab, Sandro., Galanise, Eva., and Brastianos, Priscilla K. (2018). *New molecular targets in*

meningiomas: the present and the future. www.co-neurology.com Volume 31 (6) : 740-746.

Von Achenbach, Caroline., et all. (2020). *Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02.* Translational Oncology 13 (2020) 100852 : 1-7. http://dx.doi.org/10.1016/j.tranon.2020.100852.

Wood, Daniel J., and Endicott, Jane A. (2018). *Structural Insight Into the Functional Diversity of the CDK-Cyclin Family.* Open Biology Vol.8 (180112) : 1-19. Doi : http://dx.doi/10.1098/rsob.180112.

Yang , Wookyeom., et all. (2016). *Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer. Journal Oncotarget* vol.7(31): 49481-49496. DOI: 10.18632/oncotarget.10373

Ye, Wu., Zhong-Tang Ding., Sheng-Yang Xiao., Ya, Zhan Ren., Yi, Li. (2020). *Factors Related to The Post Operative Reccurence of Atypical Meningiomas.* Frontiers in Oncology vol.10 (503) : 1-8. Doi : 10.3389/fonc.2020.00503.

DAFTAR PUSTAKA

Almutrafi, Amna., Bashawry, Yara., AlShakweer, Wafaa., Al-Harbi, Musa., Altwairgi, Abdullah and Al-Dandan, Sadeq., (2020). *Research Article The Epidemiology of Primary Central Nervous System Tumors at the National Neurologic Institute in Saudi Arabia: A Ten-Year Single-Institution Study.* Journal of Cancer Epidemiology Volume 2020 : 1-9. https://doi.org/10.1155/2020/1429615.

Apra, Caroline., Peyre, Matthieu., and Kalamarides. Michel. (2018). *Current treatment options for meningioma.* Expert Review of Neurotherapeutics, Expert Reviews (formerly Future Drugs),18 (3) : 241- 249. https://doi.org/10.1080/14737175.2018.1429920.

Asghar, U., Agnieszka K., Witkiewicz A., Turner N., & Erik S. Knudsen. (2015). *The history and future of targeting cyclin-dependent kinases in cancer therapys.* Nat Rev Drug Discov; 14(2): 130-146. doi:10.1038/nrd4504

Benson, VS., Pirie, K., Green, J., Casabonne, D., and Beral, V. (2008). *Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort.* Br J Cancer. 99(1):185-90doi:10.1038/sj.bjc.6604445.

Brown, Nicholas R., Korolchuk, Svitlana., Martin, Mathew P., Stanley, Will A., Moukhametzianov, Rouslan., Noble , Martin E.M. & Endicott, Jane A. (2015). *CDK1 structures reveal conserved and unique*

features of the essential cell cycle CDK. NATURE COMMUNICATIONS (6) : 6769. P : 1-11. DOI: 10.1038/ncomms7769

Ching Wu, Jau. (2014). *Risk factors of meningioma.* Journal of Chinese Medical Association 77 : 451-452. http://dx.doi.org/10.1016/j.jcma.2014.07.005.

Choy, Winward., Kim, Won., Nagasawa, D., Stramotas, S., Yew, A., Gopen, Q., Parsa, AT., and Yang, Isaac. (2011). *The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.* Neurosurg Focus. Vol 30 (E6) : 1-12. DOI: 10.3171/2011.2.FOCUS1116.

Commins, Deborah L., Atkinson, Roscoe D., and Burnett, Margaret E. (2007). *Review of meningioma histopathology.* Neurosurg Focus 23 (4): 1-9. DOI: 10.3171/FOC-07/10/E3.

Cossu, Giulia et all. (2016). *Meningiomas 'Management : An Update of he Literature'.* Researchgate Neurooncology Chapter 15 : 361-372. Doi : 10.5772/62929.

Dickson, M.A., and Schwartz, G.K. (2009). *Development of cell-cycle inhibitors for cancer therapy.* Current Oncology Volume 16 (2) : 36-40.

Domingues, P. *et al.* (2015). *'Genetic/Molecular Alterations of Meningiomas and the Signaling Pathways Targeted', Oncotarget*, 6(13), pp. 10671–10688. doi: 10.18632/oncotarget.3870

Goldbrunner, Roland et all. (2016). *EANO Guidelines for the Diagnosis and Treatment of Meningiomas.* Lancet Oncol volume 17 : e383-e391.

Ikeri, N. Z., Anunobi, C. C. and Bankole, O. B. (2018). *Progesterone Receptor Expression and Ki - 67   Labelling Index of Meningiomas in the Lagos University Teaching Hospital'*, Nigerian Postgraduate Medical Journal, 25, pp. 17–20. doi: 10.4103/npmj.npmj.

Juric, Viktorija. & Brona Murphy. (2019). *Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions. Journal of Cancer Drug Resist* 3:48-62 http://dx.doi.org/10.20517/cdr.2019.105

Kalous, Jaroslav., Denisa, Jansova,.& Andrej Susor. (2020). *Role of Cycli-Dependent Kinase 1 in Translational Regulation in a M-Phase. Journal   MDPI   vol.9(1568)   :   5-14* https://doi.org/10.3390/cells9071568.

Kemenkes RI. (2019). *Pedoman Nasional Pelayanan Kedokteran Tumor Otak.* Jakarta : Komite Penanggulangan Kanker Nasional.

Kim, Min Soo., et all. (2014). *Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas.*

J Neurosurg 121:1189–1200. http://thejns.org/doi/abs/10.3171/2014.7.JNS132661.

Kumar, V., Abbas, A. K. and J. C. Aster, (eds) (2015) 'The Cell as a Unit of Health and Disease', in Robbins and Cotran Pathologic Basis of Disease. 9th edition. Philadelphia : Saunders, an imprint of Elsevier Inc., pp. 25-26.

Louis, David N et all. (2021*). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.* Neuro-Oncology 23(8), 1231–1251. doi:10.1093/neuonc/noab106.

Ogasawara, Christian., Philbrick, Brandon D., and Adamson, Cory D. (2021). *Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions.* Biomedicines 9, 319 : 1-23. https://doi.org/10.3390/biomedicines9030319.

Ostrom, Quinn T., Patil, Nirav., Cioffi, Gino., Waite, Kristin., Kruchko, Carol., and Sloan Jill S. Barnholtz. (2020). *CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017.* Neuro-Oncology 22(S1), 1–96, 2020. doi:10.1093/neuonc/noaa200

Patel, JP., Jansari, TR., and Chaudhari, VV. (2019). *Clinicopathological study of Meningioma.* Tropical Journal of Pathology and

Microbiology Volume 6 Number 1 : 9-17. DOI:

https://doi.org/10.17511/jopm.2020.i01.02.

Perry, A., Louis, D.N., Budka, H., von Deimling, A., Sahm, F., Rushing, E.j. (2016). *"Meningioma" in WHO Classification of Tumours of The Central Nervous System 4th edition.* Lyon : International Agency for Research on Cancer (IARC). pp. 232-245

Peyressatre, Marion., Prevel, Camille., Pellerano, Morgan and May C. Morris. (2015). *Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors.* Cancers 2015, 7 : 179-237. doi:10.3390/cancers7010179

Santamarıa, David., et all. (2007). *Cdk1 is sufficient to drive the mammalian cell cycle.* Nature Vol 448 : 811-815. doi: https://doi.org/10.1038/nature06046.

Schniederjan, Matthew J. (2018). *Biopsy Intrepretation of The Central Nervous System 2nd Edition.* Philadelpia : Wolter Klower.

Sung, Wen Wei., . (2014). *High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.* BMC Cancer 2014, 14:951 http://www.biomedcentral.com/1471-2407/14/951

Venura, Vyshak Alva., Santagatab, Sandro., Galanise, Eva., and Brastianos, Priscilla K. (2018). *New molecular targets in*

meningiomas: the present and the future. www.co-neurology.com Volume 31 (6) : 740-746.

Von Achenbach, Caroline., et all. (2020). *Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02.* Translational Oncology 13 (2020) 100852 : 1-7. http://dx.doi.org/10.1016/j.tranon.2020.100852.

Wood, Daniel J., and Endicott, Jane A. (2018). *Structural Insight Into the Functional Diversity of the CDK-Cyclin Family.* Open Biology Vol.8 (180112) : 1-19. Doi : http://dx.doi/10.1098/rsob.180112.

Yang , Wookyeom., et all. (2016). *Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer. Journal Oncotarget* vol.7(31): 49481-49496. DOI: 10.18632/oncotarget.10373

Ye, Wu., Zhong-Tang Ding., Sheng-Yang Xiao., Ya, Zhan Ren., Yi, Li. (2020). *Factors Related to The Post Operative Reccurence of Atypical Meningiomas.* Frontiers in Oncology vol.10 (503) : 1-8. Doi
tabulasi data
: 10.3389/fonc.2020.00503.

no	no.sampel	usia	jenis kelamin	lokasi	gejala klinis	tipe meningioma	grade	CDK1	CDK1 persen	hasil kali	CDK4	CDK4 persen	hasil kali
1	H02.19.1714	1	2	5	1	3	1	2	60	120	2	50	100
2	H01.19.2264	1	2	5	5	1	1	1	60	60	1	10	10
3	H01.19.2120	1	1	1	1	1	1	1	80	80	1	40	40
4	H02.19.2593	2	2	5	5	2	1	2	70	140	1	50	50
5	H01.19.1372	1	2	1	5	1	1	1	60	60	1	70	70
6	H01.16.1479	1	2	3	1	4	1	1	50	50	2	25	50
7	47487	1	2	1	5	5	1	1	80	80	1	80	80
8	40207	1	2	3	5	3	1	2	50	100	0	0	0
9	35958	1	2	3	5	5	1	1	70	70	1	70	70
10	HUH.21.151	1	2	3	5	2	1	1	50	50	1	90	90
11	HUH21.410	1	2	1	1	1	1	1	60	60	2	15	30
12	HUH.21.651	1	1	5	1	3	1	1	70	70	1	40	40
13	HUH.19.843	1	2	2	5	2	1	1	90	90	1	50	50
14	HUH.19.814	1	2	3	1	1	1	1	80	80	1	80	80
15	HUH.19.233	1	2	5	5	5	1	1	50	50	1	30	30
16	HUH.20.358	1	2	2	1	5	1	1	90	90	1	70	70
17	HUH.20.256	1	2	5	1	1	1	1	95	95	1	60	60
18	HUH.19.720	1	1	1	2	5	1	1	80	80	0	0	0
19	HUH.19.429	1	2	5	1	1	1	1	60	60	1	10	10
20	P21.0318	1	1	5	5	1	1	1	70	70	2	70	140
21	P21.0536	1	2	3	5	2	1	1	80	80	1	40	40
22	P21.0634	1	1	2	1	1	1	1	80	80	1	80	80
23	P21.0912	1	2	5	5	2	1	1	85	85	1	60	60

24	P21.1109	1	2	4	1	1	1	1	60	60	1	70	70
25	P20.2653	1	2	1	1	3	1	1	70	70	1	80	80
26	P15.0598	1	1	5	5	7	2	2	95	190	2	80	160
27	P16.2347	1	2	5	1	7	2	2	60	120	2	60	120
28	P18.1831	1	1	**5**	1	7	2	2	90	180	2	70	140
29	P18.2438	1	2	**2**	5	7	2	2	95	190	2	80	160
30	P18.4686	2	1	**2**	1	7	2	2	95	190	2	90	180
31	P18.2107	1	2	2	5	7	2	2	90	180	2	70	140
32	P18.3078	2	2	1	5	8	2	2	90	180	3	90	270
33	P18.3850	1	2	2	1	7	2	2	95	190	3	60	180
34	P18.4231	1	2	5	5	7	2	2	90	180	1	80	80
35	P19.1388	1	2	5	5	7	2	2	85	170	2	70	140
36	P19.1556	1	2	5	5	9	2	2	100	200	2	80	160
37	P19.4431	1	2	5	5	7	2	2	60	120	2	80	160
38	P20.1549	1	2	2	1	9	2	2	90	180	2	70	140
39	P21.1738	1	2	3	5	7	2	2	80	160	2	90	180
40	P21.3379	1	1	1	1	7	2	2	90	180	3	90	270
41	P22.0112	2	2	1	1	7	2	2	90	180	2	80	160
42	HUH.20.809	1	2	4	5	7	2	2	60	120	2	70	140
43	HUH.21.005	1	1	2	3	7	2	2	90	180	2	80	160
44	51055	1	2	2	1	7	2	2	80	160	2	80	160
45	43707	1	2	2	1	9	2	2	95	190	2	50	100
46	37666	2	1	5	1	7	2	2	80	160	3	80	240
47	45572	1	2	1	4	9	2	2	90	180	2	80	160
48	H01.192334	1	2	1	5	7	2	2	60	120	3	70	210
49	H01.17249	1	1	5	5	9	2	2	70	140	2	60	120

50	P17.3445	1	2	2	5	7	2	2	95	190	2	60	120
51	P20.1240	1	2	2	2	12	2	2	100	200	2	90	180
52	HUH.21.381	1	2	2	5	12	2	2	95	190	3	95	285
53	H02.17.1325	2	2	5	5	10	3	3	95	285	3	50	150
54	39025	1	2	1	5	11	3	3	80	240	3	80	240
55	44187	1	2	1	1	10	2	2	95	190	2	70	140
56	HUH.20.481	1	2	1	5	10	3	3	80	240	3	50	150
57	P19.3854	1	2	1	1	10	3	3	90	270	3	50	150
58	P19.3768	1	2	3	2	10	3	3	80	240	3	80	240
59	P17.2404	1	2	3	5	11	3	3	80	240	2	90	180
60	P17.4355	1	1	2	5	10	3	3	90	270	2	70	140
61	P17.4419	1	2	5	4	10	3	3	95	285	3	90	270
62	P18.2292	1	2	1	5	10	2	2	100	200	2	70	140
63	P17.3341	1	2	5	5	10	3	3	100	300	3	50	150
64	P17.1850	2	2	2	2	10	3	3	100	300	3	60	180
65	P18.2069	1	1	5	5	10	3	3	95	285	3	50	150

REKOMENDASI PERSETUJUAN ETIK

Nomor : 235/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 23 Mei 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22020069	No Sponsor Protokol	
Peneliti Utama	**dr. Vivi Yuniarti Talawo**	Sponsor	
Judul Peneliti	HUBUNGAN EKSPRESI CDK1 DAN CDK4 DENGAN DERAJAT HISTOPATOLOGI MENINGIOMA		
No Versi Protokol	**2**	Tanggal Versi	**20 Mei 2022**
No Versi PSP	**2**	Tanggal Versi	**20 Mei 2022**
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **23 Mei 2022** sampai **23 Mei 2023**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**		

Kewajiban Peneliti Utama:

• Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
• Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
• Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
• Menyerahkan laporan akhir setelah Penelitian berakhir
• Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
• Mematuhi semua peraturan yang ditentukan